157 related articles for article (PubMed ID: 30619765)
1. Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8
Ye J; Zou MM; Li P; Lin XJ; Jiang QW; Yang Y; Huang JR; Yuan ML; Xing ZH; Wei MN; Li Y; Shi Z; Liu H
Front Oncol; 2018; 8():631. PubMed ID: 30619765
[TBL] [Abstract][Full Text] [Related]
2. Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.
Pan D; Zhang W; Zhang N; Xu Y; Chen Y; Peng J; Chen Y; Zhang Y; Shen X
Front Pharmacol; 2021; 12():673432. PubMed ID: 34305593
[TBL] [Abstract][Full Text] [Related]
3. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
4. Oxymatrine Synergistically Potentiates the Antitumor Effects of Cisplatin in Human Gastric Cancer Cells.
Liu Y; Qin L; Bi T; Dai W; Liu W; Gao Q; Shen G
J Cancer; 2018; 9(23):4527-4535. PubMed ID: 30519359
[TBL] [Abstract][Full Text] [Related]
5. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
[TBL] [Abstract][Full Text] [Related]
6. Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model.
Jung YY; Shanmugam MK; Narula AS; Kim C; Lee JH; Namjoshi OA; Blough BE; Sethi G; Ahn KS
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30621055
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
8. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
10. [Effect of interleukin-7 on the anti-tumor function of CD8(+) T cells in patients with non-small cell lung cancer].
Zhang XH; Wang HM; Jin L; Chang R; Zu FC; Li FZ; Ku CY
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2429-2433. PubMed ID: 30138989
[No Abstract] [Full Text] [Related]
11. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
Shi SL; Zhang ZH
Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
[TBL] [Abstract][Full Text] [Related]
12. Oxymatrine Sensitizes the HaCaT Cells to the IFN-γ Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.
Gao CJ; Ding PJ; Yang LL; He XF; Chen MJ; Wang DM; Tian YX; Zhang HM
Inflammation; 2018 Mar; 41(2):606-613. PubMed ID: 29218605
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
14. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
17. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
18. Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-β1 signaling pathway.
Shen SJ; Zhang YH; Gu XX; Jiang SJ; Xu LJ
J Integr Med; 2017 May; 15(3):242-251. PubMed ID: 28494854
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
20. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
